Murdoch Children's Research Institute
Parkville, Victoria, 3052, Australia
Location status: Recruiting
NCT Number: NCT05394363
Generation Victoria (GenV) is a longitudinal, population-based study of Victorian children and their parents that will bring together data on a wide range of conditions ,exposures and outcomes. GenV blends study-collected, study-enhanced and linked data. It will be multi-purpose, supporting observational, interventional, health services and policy research within the same cohort. It is designed to address physical, mental and social issues experienced during childhood, as well as the antecedents of a wide range of diseases of ageing. It seeks to generate translatable evidence (prediction, prevention, treatments, services) to improve future wellbeing and reduce the future disease burden of children and adults.
The GenV Cohort 2020s is open to all children born over a two-year period, and their parents, residing in the state of Victoria Australia. The GenV Cohort 2020s is preceded by an Advance Cohort of children born between 5 Dec 2020 and 3 October 2021, and their parents. This comprises all families recruited at GenV's Vanguard hospital (Joan Kirner Women's and Children's) and at birthing hospitals throughout Victoria as GenV scaled up to commence recruiting for the GenV Cohort 2020s. The Advance Cohort have ongoing and full participation in GenV for their lifetime unless they withdraw but may have less complete data and biosamples.
Interested in participating?
Request Info1 day and older
All sexes
Observational
Parkville, Victoria, 3052, Australia
Location status: Recruiting
GenV aims to create large, parallel whole-of-state birth and parent cohorts for discovery and interventional research. The four cornerstones of GenV's first decade are:
Additional foundations activities are:
GenV focuses on 10 big issues: COVID, healthy pregnancy, healthy newborns, equity, climate & environment, mental health, healthy development, allergy & immunity, infection, and obesity & diabetes, with a cross cutting commitment of population genomics. These focus areas drive current planning for data collection but are not intended to be exhaustive and may change over the life of the project.
GenV partnered with all birthing hospitals across Victoria (i.e. 58 hospital sites). In-hospital face-to-face recruitment took place during the newborn period (December 2020 - November 2023). Recruitment visits were completed by trained study staff with clinical and/or research backgrounds, including initial GenV-collected data and biosamples. GenV remains open to eligible families through phone and/or self-guided recruitment.
Participant-provided data are collected digitally (e.g. via website or smart phone app) about four times per year from age 3 months to 1 year, then 6-12 monthly until 5 years, taking 3-20 minutes per session. A face-to-face visit is planned for when the index child is around 6-years of age, completed by trained study staff with clinical and/or research backgrounds. The project duration is expected to be at least 10 years and potentially lifelong for its participants, dependent on study funding and willingness to continue.
GenV estimated that the sampling frame for the main Cohort 2020s would comprise 150,000 children,150,000 birthing parents, and 130,000 (i.e. for 90 percent of children) second parents. GenV's recruitment rate is around 30% of all Victorian families with an eligible child. With a current sample size of 50,000 children, calculations show that this can detect odds ratios of around 1.3 for an outcome with 1.5% prevalence and an exposure with 20% prevalence.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(Children):
Inclusion criteria
(Adults):
Exclusion criteria
Time frame: Point of consent until study completion (up to 10 years)
Assessed by analysis of records in the study-specific Participant Relationship Management System (PRMS)
Time frame: Point of consent until study completion (up to 10 years)
Assessed by analysis of records in the study-specific Participant Relationship Management System (PRMS), e-Consent platform and GenV data repository
Time frame: Point of consent until study completion (up to 10 years)
Assessed by analysis of records in the study-specific Participant Relationship Management System (PRMS), e-Consent platform and GenV data repository
Time frame: Point of consent until study completion (up to 10 years)
Assessed by analysis of records in the study-specific Participant Relationship Management System (PRMS), e-Consent platform and GenV Laboratory Information Management System (LIMS)
Time frame: Point of consent until study completion (up to 10 years)
Assessed by analysis of the GenV data access registry
Time frame: Point of consent until study completion (up to 10 years)
Assessed by analysis of GenV Integrated Studies Register
Time frame: Point of consent until study completion (up to 10 years)
Assessed by analysis of GenV Integrated Studies Register
Time frame: Point of consent until study completion (up to 10 years)
Assessed by analysis of shared study participant relationship management system data
Time frame: Point of consent until study completion (up to 10 years)
Assessed by analysis of shared study participant relationship management system data
Contact information is provided by the study sponsor or research team.
GenV Cohort Coordinator
CONTACT
GenV Cohort Design Lead
CONTACT
Murdoch Childrens Research Institute
Other
Generation Victoria Cohort 2020s. A Statewide Longitudinal Cohort of Victorian Children and Their Parents
Acronym: GenV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07569172
Allergies, Anemia
Taabo, Côte d’Ivoire
View Trial DetailsNCT07084103
Behavior, Congenital Abnormalities
Sakarya, Türkiye/Sakarya, Turkey (Türkiye)
View Trial DetailsNCT06945016
Anti-obesity Agents, Bariatric Surgery
Elst, Gelderland, Netherlands
View Trial DetailsNCT06548126
Adjustment, Behavior
Tempe, Arizona, United States
View Trial Details